Jazz Pharmaceuticals gets FDA OK for cataplexy drug as it prepares to replace old cash cow

The Irish pharma announced Wednesday that Xywav, treating cataplexy and excessive daytime sleepiness associated with narcolepsy in patients older than seven years, has been given the green light by US regulators. This is the third FDA approval granted to Jazz in the last 16 months and the second narcolepsy-related drug after Sunosi was OK’ed in March 2019.